Abstract

&#9660Glatiramer* acetate (Copaxone - Teva) was first marketed in the UK last year as a treatment for reducing the "frequency of relapses in ambulatory patients with relapsing-remitting multiple sclerosis characterised by at least one clinical relapse over the preceding two-year period".1 Here, we assess the place of this drug.